Pharma Groups Warn Congress Over Broader Compulsory Licensing
Industry associations representing multinational and domestic drugmakers say patent flexibility could hurt investment and innovation.
Industry associations representing multinational and domestic drugmakers say patent flexibility could hurt investment and innovation.